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Background: In the fields of traumatology and orthopaedics staphylococci are the most frequently isolated
pathogens. Staphylococcus aureus and Staphylococcus epidermidis are known to be the major causative agents of
osteomyelitis. The increasing number of multiresistant Staphylococcus aureus and resistant coagulase-negative
staphylococci as a trigger of complicated osteomyelitis and implant-associated infections is a major problem.
Antibiotic therapy fails in 20% of cases. Therefore the development of novel antibiotics becomes necessary.
Methods: This study analyses tigecyclin, the first antibiotic of the glycylines, as a potential therapy for osteomyelitis
caused by multiresistant Staphylococcus aureus. Therefore its intracellular activity and the potential use in
polymethylmetacrylate-bone cement are examined. The intracellular activity of tigecyclin is determined by a human
osteoblast infection model. The investigation of the biomechanical characteristics is conducted concerning the ISO
5833-guidelines.
Results: Tigecyclin shows in vitro an intracellular activity that ranges between the antimicrobial activity of
gentamicin and rifampicin. A significant negative effect on the biomechanical characteristics with an impaired
stability is detected after adding tigecyclin to polymethylmetacrylate-bone cement with a percentage of 1.225% per
weight.
Conclusions: This study shows that tigecyclin might be a potent alternative for the systemic therapy of
osteomyelitis and implant-associated infections whereas the local application has to be reconsidered individually.
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Osteomyelitis is an inflammatory process caused by in-
fective microorganism [1]. With a percentage of 80% [2]
S. aureus (Staphylococcus aureus) is the most common
pathogen of osteomyelitis [1,3]. Implant-associated infec-
tions are also often caused by S. epidermidis (Staphylo-
coccus epidermidis) [3,4] and occur with a rate from 3-
33% [5]. The therapy of osteomyelitis still represents a
major challenge [3]. A single antibiotic agent is the
standard therapy for osteomyelitis in its early stages [1].
In order to cure the chronic stages of this bone infection
a combined therapy has to be chosen, which consists of
a combination of two antibiotic substances and the* Correspondence: Carolin.Kreis@ukmuenster.de
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reproduction in any medium, provided the orsurgical approach, which implies the surgical debride-
ment, the implant removal or the two-step replacement
[1,3,6,7]. The combination of rifampicin plus another
antibiotic agent shows efficient therapeutic results for
the implant-associated infection caused by S. aureus [1].
However, antibiotic therapy fails in 20% of cases. This
might be explained by the ability of S. aureus to invade
human osteoblast cells [1-3] and to survive intracellu-
larly [1,2]. Thereby, S. aureus can change its phenotype
into SCVs (small colony variants), which is a bacterial
subpopulation that is well adapted for long-term intra-
cellular persistence [3,8]. In general SCVs have a reduced
metabolism and have an increased resistance against
antibiotics, especially against aminoglycosides [3,8,9].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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foreign material surfaces and form biofilm [1,3,7,10,11].
The bacterial biofilm is a matrix out of polysaccharides
and proteins [10] and acts as a diffusion barrier that in-
hibits the diagnosis and eradication of bacteria [7].
PMMA (polymethylmetacrylate)-bone cement loaded
with antibiotic substances is an established treatment for
infected endoprotheses for over 40years with good long-
term results [6,12]. Antibiotic-loaded bone cement
works as a local antibiotic-carrier with the function of a
drug-delivery-system to achieve high antibiotic levels lo-
cally [12-14] and to decrease the infection rate [12].
PMMA-bone cement is most commonly loaded with
aminoglycosides [15], especially with gentamicin as a
good prophylaxis as well as a treatment for implant-
associated infections [16]. It was shown that PMMA-
bone cement loaded with gentamicin inhibits 80% of S.
aureus-biofilm synthesis [17]. Despite these options the
treatment of osteomyelitis remains a challenging prob-
lem [3]. MRSA- and VRSA- infections are increasing as
well as the number of antibiotic-resistant S. aureus and
S. epidermidis [3,12]. Because of increasing resistance
against gentamicin [12,18] and vancomycin [18] new
[16] or combined [12] antibiotics have to be added to bone
cement. Furthermore 41% of clinical isolated S. aureus are
resistant against gentamicin [16]. S. aureus also has the
ability to grow on bone cement loaded with gentamicin
[19]. S. epidermidis is able to adhere to bone cement
in vivo [20] and in vitro and to synthesize biofilm on bone
cement loaded with gentamicin [21]. Multiresistant patho-
gens are a major therapeutic problem [22]. Therefore new
antibiotics are essential to minimize pathogens and to
optimize the therapy of osteomyelitis [23]. In this context
tigecyclin has been developed [24], which is the first anti-
biotic of the glycylines with efficacy against many import-
ant pathogens, multiresistant strains, mixed infections and
problematic pathogens [23,24]. In clinical daily routine
tigecyclin shows good therapeutic efficacy against
intraabdominal infection, skin- and soft-tissue infections
[23,24]. Tigecyclin shows activity against infection caused
by MRSA [25] and against biofilm associated pathogens
[26]. Furthermore tigecyclin is absorbed by bone tissue
after intravenous application [27]. Till 2007 only few
tigecyclin-resistant S. aureus-strains were known [28],
there are even some rifampicin-resistant S. epidermidis-
strains that were sensitive against tigecyclin [4]. This study
investigates tigecyclin as a potential therapy for osteomye-
litis caused by multiresistant S. aureus. Its intracellular ac-
tivity is determined in comparison to gentamicin and
rifampicin by a human osteoblast infection model [29].
The potential use in PMMA-bone cement is conducted
concerning the ISO 5833-guidelines compared to genta-
micin (International Organization for Standardization: Im-
plants for surgery - Acrylic resin cements. 2002).Methods
Human osteoblast infection model
To determine the intracellular activity of tigecyclin a pri-
mary human osteoblast model modified by Haslinger-
Loeffler et al. [29] is established. Due to the capacity of S.
aureus to enter the intracellular environment two different
S. aureus-strains (S. aureus Cowan I ATCC 12598, S. aur-
eus Subspezies Rosenbach ATCC 49230) with different in-
vasion characteristics (Cowan I: 100%, ATCC 49230:
180%) are used. S. carnosus TM 300 allegorizes the nega-
tive control without capacity to enter the intracellular en-
vironment. On the previous day of the assay the human
osteoblast cells are seeded together with 1ml growth
medium into 12-well tissue culture plates with a number
of 1×105/well. The growth medium consists of Minimum
Essential Medium (MEM), HAM’s F12 (MEM:HAM’s
F12 = 1:1), 10% fetal calf serum (FCS), penicillin/strepto-
mycin (penicillin 100 Units/ml, streptomycin 100 mg/ml),
10nM Dexamethason, 0,2 mML-Ascorbat-2-Phosphate
and 10 mM b-Glycerolphosphate. Prior to the investiga-
tion the bacteria strains have to be grown overnight. Bac-
terial cell numbers are measured spectrophotometrically
at 540 nm and diluted with 1ml phosphate-buffered saline,
pH7.4 (PBS) and with 1% HSA to ensure a cell number of
5×108 bacteria/ml. At the beginning of the assay the con-
fluent grown osteoblast cells are washed with MEM/
HAM’s F12 (1:1) and then incubated with the cultured
bacteria and 1ml assay medium, which consists of MEM/
HAM’s F12 (1:1) and 1% HSA, for 30 min at ambient
temperature followed by 3h at 37°C and 5% CO2. In order
to assure a multiplicity of infection (MOI) of 100 with an
optical density (OD) of 1, bacteria are added with the fol-
lowing amounts: S. carnosus TM 300: 38 μl, S. aureus
Cowan I ATCC 12598: 19 μl, S. aureus Subspezies
Rosenbach ATCC 49230: 16 μl. After incubation the exter-
nal S. aureus are inactivated by 20 mg/ml lysostaphin.
Then 1ml MEM/HAM’s F12 (1:1) + 10% FCS is added to
the osteoblast cells with the intracellular persisting bac-
teria. For the following incubation for 20h or 40h at 37°C
and 5% CO2 10 μg/ml tigecyclin, 10 μg/ml gentamicin,
7 μg/ml rifampicin or the combinations tigecyclin/
gentamicin or tigecyclin/rifampicin are added. The anti-
biotic concentrations were chosen according to high level
doses that can be reached after intravenous application in
serum and tissue [31-33]. Both S. aureus strains were
tested sensitive to the antibiotics tigecyclin, gentamicin
and rifampicin (Table 1). To determine the internalization
and the success of the antibiotics the cells are detached
from the wells after 20 h or 40 h and washed consistently
with PBS, so that the osteoblast cells are destroyed and
only the intracellular bacteria are able to remain. Bacteria
are resuspended with 1ml aqua dest and cell enumeration
of colony forming units (CFU) is performed by serial dilu-
tion and plate counting on Mueller-Hinton agar plates.
Table 1 Antimicrobial resistant profiles of the S. aureus
strains used in this study







The S. aureus strains Cowan I ATCC 12598 and S. aureus Subspezies Rosenbach
ATCC 49230 were tested for their sensitivity towards antimicrobial compounds
used in this study by Vitek-2 (bioMérieux). The minimal inhibitory
concentrations (MHK) were interpretated according to the guidelines of
EUCAST and CLSI 2012 D.
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The investigation of the cure time [min] of PMMA-bone
cement loaded with tigecyclin versus customary bone ce-
ment loaded with gentamicin is performed concerning
the ISO 5833-standards. The antibiotics are added with
a weight proportion of 1.225%. After 1min the com-
pound of PMMA-bone cement and antibiotic is touched
with a dry and clean glove every 15seconds. To deter-
mine the compressive strength [MPa] PMMA-bone ce-
ment cylinders with a length of 12 mm (± 0,1 mm) and
a diameter of 6mm (± 0,1 mm) are produced by the ISO
5833-guidlines with the antibiotics tigecyclin and genta-
micin each with a weight proportion of 1.225%. The cyl-
inders are placed into the uniaxial testing machine
(Zwick/Roell), which operates a constant compression
with a speed of 22 mm/min until the material shows
breakage. The compressive strength [MPa] for each test
cylinder is then calculated using the following formula:
compressive strength [MPa] = (force [N])/(πr2), in which
the force applied until breakage is divided by the cross-
sectional area of the cylinder. The bending strength
[MPa] and the bending modulus [MPa] of PMMA-bone
cement loaded with tigecyclin or gentamicin (1.225% per
weight) are examined conducting ISO 5833-standards
with created cement bars with the measure of 75 mm
(± 0.1 mm) length, 10 mm (± 0.1 mm) width and 3.3 mm
(± 0.1 mm) depth. The test bars are placed into the uni-
axial testing machine (Zwick/Roell) and a four-point bend-
ing test is accomplished. Operating the crosshead with a
speed of 5 mm/min ± 1 mm/min the deflection under the
specimen and the applied force are recorded until break-
age. The bending strength [MPa] and the bending modu-
lus [MPa] are calculated afterwards taking the defined
measurements, the deflection under certain loads and the
force at breaking point into account with the formulas:
bending strength [MPa] = 3Fa/bh2, bending modulus
[MPa] = (ΔFa/4fbh3) × (3l2-4a2).
Statistical analysis
Statistical analysis was performed with the Mann-Whithey-
U-test for the results of the infection model. The results of the
biomechanical testings besides the bending modulus werestatically analysed by the unpaired t-test. Statistical analysis for
the bending modulus was performed by the unpaired t-test
with Welch correction. A value of * p ≤ 0.05 was consideres
siginificant in all cases.
Results
Human osteoblast infection model
Figure 1 shows the relative time-dependent decrease of
intracellular bacteria when applying antibiotics to
infected osteoblasts. A significant time-dependent differ-
ence is noted for the S. aureus strain Cowan I and 49230
after treating the infected osteoblasts with tigecyclin for
20 h and 40 h. The same time-dependent decreases after
40 h concerning the intracellular bacteria are noticed for
all used antibiotics and their combinations. The S.
carnosus strain TM 300, as a non-invasive control,
served as a negative control. After incubation for 20h
and 40 h cells stimulated with tigecyclin show significant
decrease of the intracellular bacteria within the single-
use (p = 0.0) and for the combination tigecyclin/gentami-
cin (p = 0.0) compared to gentamicin. No significant dif-
ference can be noted when comparing the combination
tigecyclin/gentamicin (p = 0.61-1.0) to tigecyclin. Signifi-
cant reduction of the intracellular bacteria is investigated
for the duration of 20 h and 40 h for the application
with rifampicin compared to gentamicin (p = 0.0) and to
tigecyclin (p = 0.0). Parallel results are observed for the
comparison of the combination rifampicin/tigecyclin
with tigecyclin in Cowan I (p = 0.0). No significant differ-
ence is found between the combination rifampicin/
tigecyclin and rifampicin (p = 0.16-1.0). A significant de-
crease of intracellular bacteria can be observed after 40 h
incubation with tigecyclin compared to 20 h incubation.
Biomechanics
The investigation of the biochemical characteristics
shows a significant change after adding 1.225% of ti-
gecyclin per weight to PMMA-bone cement compared
to customary products with gentamicin. Figure 2 shows
the average cure time [min] of the 2 investigation
groups. The average cure time of tigecyclin-loaded bone
cement is 17min and therewith significantly (p < 0.0001)
extended compared to the customary gentamicin-loaded
bone cement. This investigation group only requires
4,42 min for the curing process. The average compressive
strength [MPa] of the 2 different groups is shown in
Figure 2. The average compressive strength for tigecyclin
loaded PMMA-bone cement is 78.4 MPa and 93.41 Mpa
for PMMA-bone cement loaded with gentamicin. The
average maximum compressive strength in both investi-
gation groups is well exceeding to the required mini-
mum strength of 70 MPa by the ISO, although it is
significantly higher for gentamicin (p = 0.0001). Figure 2
also shows the bending strength [MPa] and the bending
Figure 1 Relative internalization rate [%] after 20 h versus 40 h. Primary human osteoblasts were infected with S. aureus Cowan I ATCC
12598, S. aureus Subspezies Rosenbach ATCC 49230 and S. carnosus TM 300 (MOI = 100) followed by treatment with antibiotics for 20 h or
for 40 h, n = 3. The number of surviving bacteria was determined by plating and is shown in relation to S. aureus Cowan I incubated with
Gentamicin for 20h (100%). The results are shown as means ± SD of three independent experiments performed in triplicate. * p≤ 0.05.
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age bending strength for PMMA-bone cement loaded
with tigecyclin is 44.30 MPa and is below the ISO required
minimum bending strength of 50 MPa. PMMA-bone ce-
ment loaded with gentamicin shows a sufficient strength
of 56.93 MPa with a significant difference (p = 0.0408).
The average bending modulus values are well above the
required ISO minimum value of 1800 MPa. The bending
modulus amounts 2149.43 MPa to PMMA-bone cementFigure 2 Demonstration of the biomechanical results. A cure time [min
D bending modulus [MPa]. The investigation of the biochemical characteri
weight to PMMA-bone cement compared to customary products with gen
groups. The average compressive strength [MPa] of the 2 different groups
bending modulus [MPa] of the 2 investigation groups. The results are show
cure time and six independent experiments for the compressive strength,loaded with tigecyclin and 2655.15 MPa to PMMA-bone
cement loaded with gentamicin, which points out a signifi-
cance of p = 0.0387.
Discussion
The in vitro model of an osteomyelitis displays that the
effectiveness of the novel antibiotic tigecyclin has to be
ranked between gentamicin and rifampicin after incuba-
tion of 20 h and 40 h. The effectivness of rifampicin], B compressive strength [MPa], C bending strength [MPa],
stics shows a significant change after adding 1.225% of tigecyclin per
tamicin. A shows the average cure time [min] of the 2 investigation
is shown in B. C shows the bending strength [MPa] and D the
n as means ± SD of three independent experiments in case of the
bending strength and bending modulus. * p≤ 0.05.
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and in vivo studies done in 2006 and 2009, in which a
reduction of intracellular bacteria after treatment with
rifampicin could be shown [34]. In 2008 and 2009 the
synergistical effect of tigecyclin to rifampicin and genta-
micin against S.aureus could be displayed in vivo and
in vitro as a potential combined therapy against
multiresistant bacteria [30,35]. The synergistical effect of
tigecyclin to gentamicin was confirmed in our study,
whereas the additive effect of tigecyclin to rifampicin
could not be shown. It is known that gentamicin has
good activity in the extracellular space, whereas an addi-
tive effect to the effectiveness of tigecyclin cannot be
assigned by our study. However, it remains uncertain if
our results can be transferred to in vivo conditions as S.
aureus quickly developes resistances [2]. It would be sig-
nificant to search out if this has validity for tigecyclin as
well. A combination of tigecyclin and rifampicin might
be recommendable to prevent resistances. Yin et al.
show a complete bacterial eradication after a combined
treatment with tigecyclin s.c. and rifampicin p.o. in an
in vivo MRSA-osteomyelitis-model [36]. Furthermore, it
has to be examined if higher doses of tigecyclin would
on the one hand reduce the intracellular bacteria
completly and on the other hand would induce the
SCV-synthesis, which displays a handicap for antibiotic
therapy. 1995 Henry and Galloway showed that PMMA-
bone cement loaded with antibiotics is an effective ther-
apy for bone or soft tissue infections as it is possible to
reach high antibiotic levels locally without their un-
wanted side effects [13]. Since 2003 gentamicin is added
to PMMA-bone cement as the standard antibiotic sub-
stance with a broad antibacterial effectiveness, a low in-
fluence on biomechanical properties of bone cement
and a good release out of bone cement [12]. Despite the
study results it is doubtfull if tigecyclin is a potential al-
ternative to gentamicin for the local use in bone cement.
Here the biomechanical investigation of tigecyclin shows
a reduction of the stability of Palacos ®-bone cement
compared to Palacos ®-bone cement loaded with genta-
micin. It is known that bone cement loaded with genta-
micin or rifampicin shows a good local effectiveness
with reduction of implant-associated bacteria and reduc-
tion of biofilm synthesis [19,21,37]. Similar results are
not yet exciting for tigecyclin [37], which would be im-
portant to consider tigecyclin as an alternative to genta-
micin in clinical daily routine. With the help of different
models the good release of gentamicin out of bone ce-
ment could be displayed [12,38], but it is still uncertain
if a constant release of gentamicin induces the synthesis
of resistances or not [12]. Bone cement loaded with ri-
fampicin reveals a bimodal elution kinetic with a fast,
high concentrated initial release follwed by a slow,
low concentrated release [18]. Comparable studiesconcerning the release of tigecyclin out of bone cement
are missing. In actual studies there are only few resis-
tances against tigecyclin listed and it is known as an ef-
fective therapy against MRSA-infections and biofilm
associated bacteria [25,26,28,39]. Furthermore tigecyclin
reduces the expression of some important virulence
factors of S. aureus [40]. 91% of multiresistant S.
epidermidis are sensitive against tigecyclin [4]. Redvold
et al. demonstrate the good bone absorption of tigecyclin
after intravenous application [27]. On the other hand
there is less clinical data exciting concerning this novel
antibiotic substance associated with safety questions [41].
In addition Rose and Poppens demonstrate that tigecyclin
does not reduce biofilm-associated S. aureus [42].
Conclusions
In conclusion there is inconsistent result concerning
tigecyclin. Tigecyclin shows effective intracellular activity
against S. aureus with negative influence on the bio-
mechanical stability of Palacos ®-bone cement. In total
tigecyclin seems to be a possible therapy option or alter-
native in the systemic treatment of osteomyelitis because
of its good intracellular effectiveness. The local applica-
tion of tigecyclin has to be evaluated individually be-
cause of less biomechanical stability of bone cement.
Competing interests
This study was funded by the interdisciplinary center for clinical research,
Muenster (IZKF, C.K.).
Authors’ contributions
CK is the corresponding author, carried out the human osteoblast infection
model, participated in the biomechanical study and designed the
manuscript. MR participated in the design of the study and gave final
approval of the version to be published. SR carried out main parts of the
biomechanical study. NT made contributions to acquisition of date, analysis
and interpretation of data. Furthermore she conceived the human osteoblast
infection model. BL has given final approval to the human osteoblast
infection model and participated in the interpretation of data. TF conceived
of the study and its design. He participated in the design of the manuscript
and gave final approval of the version to be published. All authors read and
approved the final manuscript.
Acknowledgments
We acknowledge support by Deutsche Forschungsgemeinschaft and Open
Access Publication Fund of University of Muenster.
Funding did not influence study outcome.
Author details
1Department of Trauma, Hand and Reconstructive Surgery, University
Hospital of Muenster, Waldeyerstr. 1, 48149, Muenster, Germany. 2Institute of
Medical Microbiology, University Hospital of Muenster, Domagkstr. 10, 48149,
Muenster, Germany.
Received: 18 January 2013 Accepted: 3 June 2013
Published: 5 June 2013
References
1. Lew DP, Waldvogel FA: Osteomyelitis. Lancet 2004, 364:369–379.
2. Ellington JK, Harris M, Hudson MC, et al: Intracellular Staphylococcus Aureus
and antibiotic resistance: implications for treatment of staphylococcal
osteomyelitis. J Orthop Res 2006, 24:87–93.
Kreis et al. BMC Infectious Diseases 2013, 13:267 Page 6 of 6
http://www.biomedcentral.com/1471-2334/13/2673. Ciampolini J, Harding KG: Pathophysiology of chronic bacterial
osteomyelitis. why do antibiotics fail so often? Postgrad Med J 2000,
76:479–483.
4. Hellmark B, Unemo M, Nilsdotter-Augustinsson A, Söderquist B, et al:
Antibiotic susceptibility among staphylococcus epidermidis isolated
from prosthetic joint infections with special focus on rifampicin and
variability of the rpoB gene. Clin Microbiol Infect 2009, 15:238–244.
5. Seligson D, Klemm K: Adult posttraumatic osteomyelitis of the tibial
diaphysis of the tibial shaft. Clin Orthop Relat Res 1999, 360:30–36.
6. Buchholz HW, Elson RA, Engelbrecht E, et al: Management of deep
infection of total hip replacement. J Bone Joint Surg Br 1981,
63-B(3):342–353.
7. Trampuz A, Zimmerli W: Prosthetic joint infections: update in diagnosis
and treatment. Swiss Med Wkly 2005, 135(17–18):243–252.
8. Proctor RA, von Eiff C, Kahl BC, et al: Small colony variants: a pathogenic
form of bacteria that facilitates persistent and recurrent infections. Nat
Rev Microbiol 2006, 4:295–305.
9. von Eiff C, Peters G, Becker K: The small colony variant (SCV) concept –
the role of staphylococcal SCVs in persistent infections. Injury 2006,
37:526–533.
10. Stewart PS, Costerton JW: Antibiotic resistance of bacteria in biofilms.
Lancet 2001, 358(9276):135–138.
11. Tang H, Xu Y: Bacterial biofilms and chronic osteomyelitis. Zhongguo Xiu
Fu Chong Jian Wai Ke Za Zhi 2010, 24(1):108–111.
12. Breusch SJ, Kühn KD: Knochenzemente auf basis von
polymethylmethacrylat. Orthopade 2003, 32:41–50.
13. Henry SL, Galloway KP: Local antibacterial therapy for the management of
orthopaedic infections. Pharmacokinet considerations. Clin Pharmacokinet.
1995, 29(1):36–45.
14. Raschke MJ, Schmidmaier G: Biological coating of implants in trauma and
orthopedic surgery. Unfallchirurg 2004, 107(8):653–663.
15. Reichert P, Rutowski R, Gosk J: Application of gentamycini impregnated
polymethylmethacrylate (PMMA) (Septopal) in treatment of infected
nonunion. Own exp. Polim Med. 2007, 37(4):65–72.
16. Anguita-Alonso P, Hanssen AD, Osmon DR, et al: High rate of
aminoglycoside resistance among staphylococci causing prosthetic joint
infection. Clin Orthop Relat Res 2005, 439:43–47.
17. Neut D, Kluin OS, Crielaard BJ, et al: A biodegradable antibiotic delivery
system based on poly- (trimethylene carbonate) for the treatment of
osteomyelitis. Acta Orthop 2009, 80(5):514–519.
18. Anguita-Alonso P, Rouse MS, Piper KE, et al: Comparative study of
antimicobial release kinetics from polymethylmethacrylate. Clin Orthop
Relat Res 2006, 445:239–244.
19. van de Belt H, Neut D, Schenk W, et al: Staphylococcus aureus biofilm
formation on different gentamicin-loaded polymethylmethacrylate bone
cements. Biomaterials 2001, 22(12):1607–1611.
20. Chang CC, Merritt K: Infection at the site of implanted materials with and
without preadhered bacteria. J Orthop Res 1994, 12(4):526–531.
21. Chang CC, Merritt K: Microbial adherence on poly(methyl methacrylate)
(PMMA) surfaces. J Biomed Mater Res 1992, 26(2):197–207.
22. Barton E, MacGowan A: Future treatment options for gram-positive
infections - looking ahead. Clin Micobiol. Infect. 2009, 6:17–25.
23. Rose WE, Rybak MJ: Tigecycline: first of a new class of antimicrobial
agents. Pharmacotherapy 2006, 26(8):1099–1110.
24. Hawkey P, Finch R: Tigecycline: in-vitro performance as a predictor of
clinical efficacy. Clin Microbio Infect 2007, 13:354–362.
25. Verkade EJ, Verhulst CJ, Huijsdens XW, Kluytmans JA: In vitro activity of
tigecycline against methicillin-resistant Staphylococcus aureus, including
livestock-associated strains. Eur J Clin Microbiol Infect Dis 2010,
29(5):503–507.
26. Aslam S: Effect of antibacterials on biofilms. J of Infect Control 2008,
36:S175 e9–S175 e11.
27. Rodvold KA, Gotfried MH, Cwik M, et al: Serum, tissue and body fluid
concentrations of tigecycline after a single 100mg dose. J Antimicrob
Chemother 2006, 58(6):1221–1229.
28. Anstead GM, Quinones-Nazario G, Lewis JS 2nd: Treatment of infections
caused by resistant Staphylococcus aureus. Methods Mol Biol 2007,
391:227–258.
29. Haslinger-Loeffler B, Kahl BC: Multiple virulence factors are required for
Staphylococcus aureus-induced apoptosis in endothelial cells. cellular
microbiology. Grundmeier Met al 2005, 7(8):1087–1097.30. Duez JM, Adochitei A, Péchinot A, et al: In vitro combinations of five
intravenous antibiotics with dalfopristin-quinupristin against
Staphylococcus aureus in a 3-dimensional model. J Chemother 2008,
20(6):684–689.
31. Demczar DJ, Nafziger AN, Beritino JS: Pharmacokinetics of gentamicin at
traditional versus high doses: implications for once-daily aminoglycoside
dosing. Antimicrob Agents Chemother 1997, 5:115–119.
32. EUCAST: Technical note on tigecycline. Clin Microbiol Infect 2006,
12:1147–1149.
33. Roth B: Penetration of parenterally administered rifampicin into bone
tissue. Chemotherapy 1984, 30(6):358–365.
34. Sandberg A, Hessler JHR, Skov RL, et al: Intracellular activity of antibiotics
against Staphylococcus aureus in a mouse peritonitis model. Antimicrob
Agents Chemother 2009, 53(5):1874–1883.
35. Entenza JM, Moreillon P: Tigecycline in combination with other
antimicrobials: a review of in vitro, animal and case report studies. Int J
Antimicrob Agents 2009, 34(8):1–9.
36. Yin LY, Lazzarini L, Li F, et al: Comparative evaluation of tigecycline and
vancomycin, with and without rifampicin, in the treatment of
methicillin-resistant Staphylococcus aureus experimental osteomyelitis in
a rabbit model. J Antimicrob Chemother 2005, 55:995–1002.
37. Trampuz A, Zimmerli W: Antimicrobial agents in orthopaedic surgery:
prophylaxis and treatment. Drugs 2006, 66(8):1089–1105.
38. Seldes RM, Winiarsky R, Jordan LC, et al: Liqiud gentamicin in bone
cement: a laboratory study of a potentially more cost-effective cement
spacer. L Bone Joint Surg 2005, 87:268–272.
39. Kandemir O, Oztuna V, Colak M, et al: Comparison of the efficacy of
tigecycline and teicoplanin in an experimental methicillin-resistant
Staphylococcus aureus osteomyelitis model. J Chemother 2008,
20(1):53–57.
40. Smith K, Gould KA, Ramage G, et al: Influence of tigecycline an expression
of virulence factors in biofilm-associated cells of methicillin-resistant
Staphylococcus aureus. Antimicrob Agents Chemother 2010:380–387.
41. Grossi PA: Early appropiate therapy of Gram-positive bloodstream
infections: the conservative use of new drugs. Int J of Antimicrob Agents
2009, 34S:S31–S34.
42. Rose WE, Poppens PT: Impact of biofilm on the in vitro activity of
vancomycin alone and in combination with tigecycline and rifampicin
against Staphylococcus aureus. J Antimicrob Chemother 2009, 63:485–488.
doi:10.1186/1471-2334-13-267
Cite this article as: Kreis et al.: Therapy of intracellular Staphylococcus
aureus by tigecyclin. BMC Infectious Diseases 2013 13:267.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
